Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients

Cytokinetics, Inc. and Amgen, Inc. previously reported that the Phase III GALACTIC-HF clinical trial of heart failure drug omecamtiv mecarbil met the primary endpoint but missed a key secondary endpoint and now the full results show that the overall benefit was modest. But while Cytokinetics sees a path forward in certain patients, Amgen has not determined whether this treatment benefit is worth pursuing further.

The detailed GALACTIC-HF results were presented at the American Heart Association (AHA) virtual annual meeting on 13 November. The trial...